SeanMDonahoeMDFACC

Cardiology • Riverhead, NY

Non-Invasive Cardiology, Preventive Cardiology

Director of CV Research

Join to view full profile

Dr. Donahoe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Donahoe's full profile

Already have an account?

Office
951 Roanoke Avenue
Riverhead, NY 11901
Phone+1 631-727-7773

Education & Training

NYP Hosp-Weill Cornell Med CtrFellowship in Cardiovascular Medicine, 2006 - 2009
Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
Brigham and Women's HospitalInternship, Internal Medicine, 2003 - 2004
New York University School of MedicineClass of 2003

Certifications & Licensure

FL State Medical License 2024 - 2027
NY State Medical License 2006 - 2025
MA State Medical License 2005 - 2007
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease
American Society of Nuclear cardiologyBoard Certified
National Board of EchocardiographyTestamur

Awards, Honors, & Recognition

AOA
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACC) American College of Cardiology

Clinical Trials

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Start of enrollment: 2010 Oct 01
Completed
Phase 3
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke Start of enrollment: 2022 Dec 05
TERMINATED
PHASE3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial Start of enrollment: 2022 Dec 14
ACTIVE_NOT_RECRUITING
PHASE3
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease Start of enrollment: 2018 Oct 30
ACTIVE_NOT_RECRUITING
PHASE3
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 Start of enrollment: 2019 Sep 23
Completed
Phase 3
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) Start of enrollment: 2017 Mar 06
Completed
Phase 3
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) Start of enrollment: 2017 Mar 02
Completed
Phase 3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD Start of enrollment: 2019 Dec 12
ACTIVE_NOT_RECRUITING
PHASE3
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% Start of enrollment: 2020 Sep 14
COMPLETED
PHASE3
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo Start of enrollment: 2016 Dec 22
Completed
Phase 3
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) Start of enrollment: 2022 Apr 19
COMPLETED
NA
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Start of enrollment: 2014 Jan 24
Completed
Phase 4
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events Start of enrollment: 2013 Apr 25
Completed
Phase 3
A Study of Evacetrapib in High-Risk Vascular Disease Start of enrollment: 2012 Oct 01
Terminated
Phase 3
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Start of enrollment: 2019 Jun 11
ACTIVE_NOT_RECRUITING
PHASE3
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia Start of enrollment: 2014 Oct 30
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

14 citations
Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study
Christian T. Ruff, Marc P. Bonaca, Joshua M. Kosowsky, Michael J. Conrad, Sabina A. Murphy
Journal of Thrombosis and Thrombolysis. 2013-01-18
499 citations
Diabetes and Mortality Following Acute Coronary Syndromes
Sean M. Donahoe, Garrick C. Stewart, Carolyn H. McCabe, Satishkumar Mohanavelu, Sabina A. Murphy
JAMA. 2007-08-15
3 citations
Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy.
Sean M Donahoe, Marc S. Sabatine
Expert Review of Pharmacoeconomics & Outcomes Research. 2005-12-01

Press Mentions

Cardiologist Discovers Lifes Work After Personal TragedyNovember 10th, 2022

Professional Memberships

American College of Cardiology - ACC
Fellow
American Society of Echocardiography - ASE
Member
Alpha Omega Alpha Honor Medical Society - AOA
Member